A randomised controlled trial on roles of prostaglandin E1 nebulization among patients undergoing one lung ventilation

Li, Pengyi; Gu, Lianbing; Tan, Jing; Song, Zhenghuan; Bian, Qingming; Jiao, Dian; Xu, Zeping; Wang, Lijun

doi:10.1186/s12890-022-01831-4

Table 3 The levels of PaO₂, PaO₂/FiO₂, SaO₂, SPO₂, ETCO₂, PaCO₂, MAP, PAW and QS/QT among three groups

From: A randomised controlled trial on roles of prostaglandin E1 nebulization among patients undergoing one lung ventilation

Indicator	Group	T1	T2	T3	T4	T5	T6
PaO_2*, mmHg
	A	271.5 ± 37.5	153.4 ± 32.2	132.0 ± 28.5	121.0 ± 27.3	115.4 ± 34.9	153.4 ± 45.3
	B	175.0 ± 51.1^a	88.7 ± 27.6^a	89.2 ± 29.4^a	74.4 ± 17.8^a	81.4 ± 21.4^a	99.5 ± 25.0^a
	C	172.5 ± 90.8^a	84.9 ± 17.1^a	82.3 ± 15.9^a	76.5 ± 17.5^a	80.1 ± 25.3^a	101.1 ± 22.0^a
PaO₂/FiO₂, mmHg
	A	452.5 ± 62.4	255.6 ± 53.6	219.9 ± 47.5	201.8 ± 45.5	192.4 ± 58.3	255.6 ± 75.6
	B	437.4 ± 127.8	221.8 ± 69.0^a	222.9 ± 73.6	185.9 ± 44.4	203.5 ± 53.5	248.9 ± 62.5
	C	397.6 ± 142.8	212.3 ± 42.8^a	205.7 ± 39.7	191.3 ± 43.9	200.2 ± 63.4	252.8 ± 54.9
SaO₂, %
	A	100.0 ± 0.0	98.8 ± 0.9	98.4 ± 1.3	97.5 ± 1.5	97.9 ± 1.4	98.9 ± 1.4
	B	99.3 ± 0.7	95.2 ± 2.4^a	95.2 ± 2.9^a	93.6 ± 3.1^a	95.0 ± 2.1^a	97.2 ± 1.7^a
	C	98.6 ± 2.3	95.4 ± 2.8^a	94.8 ± 2.6^a	93.9 ± 3.0^a	94.5 ± 2.8^a	97.2 ± 1.7^a
SpO₂, %
	A	99.5 ± 0.7	99.1 ± 1.1	98.2 ± 3.0	98.3 ± 1.5	98.3 ± 1.5	99.4 ± 0.9
	B	99.2 ± 1.2	97.1 ± 2.2^a	96.6 ± 2.1^a	95.2 ± 2.4^a	96.3 ± 2.1^a	98.1 ± 1.5
	C	98.0 ± 5.9	96.4 ± 4.1^a	95.4 ± 4.1^a	94.6 ± 4.3^a	95.3 ± 3.5^a	97.4 ± 4.1
PaCO₂, mmHg
	A	42.9 ± 6.0	43.3 ± 6.2	41.8 ± 5.8	40.1 ± 5.8	41.6 ± 6.3	39.5 ± 6.8
	B	46.2 ± 18.1	46.3 ± 7.2	43.8 ± 4.9	42.5 ± 5.2	40.9 ± 6.1	39.4 ± 4.7
	C	43.4 ± 4.9	48.9 ± 8.4	47.1 ± 7.8	42.6 ± 6.0	40.3 ± 5.6	39.6 ± 6.0
ETCO₂, mmHg
	A	35.4 ± 5.8	36.8 ± 4.6	35.7 ± 4.1	34.7 ± 4.0	35.1 ± 4.4	34.4 ± 4.4
	B	35.2 ± 3.6	36.3 ± 4.7	35.6 ± 4.0	33.9 ± 4.6	33.1 ± 4.4	33.6 ± 3.3
	C	35.8 ± 5.9	38.3 ± 7.4	37.7 ± 7.5	35.1 ± 6.0	33.7 ± 6.3	33.8 ± 6.5
MAP_*, mmHg
	A	102.1 ± 14.7	96.5 ± 16.0	92.6 ± 16.3	94.1 ± 22.9	95.6 ± 21.3	89.3 ± 26.5
	B	72.6 ± 9.1^a	76.8 ± 11.5^a	78.4 ± 13.5^a	77.2 ± 11.8^a	70.3 ± 11.2^a	67.5 ± 10.1^a
	C	77.3 ± 12.1^a	83.9 ± 11.8^ab	84.8 ± 12.0^ab	80.8 ± 11.1^a	72.3 ± 9.5^a	68.7 ± 10.5^a
PAW, cmH₂O
	A	14.9 ± 3.2	22.5 ± 3.7	23.0 ± 3.4	23.6 ± 4.5	24.3 ± 4.5	24.3 ± 3.9
	B	15.1 ± 3.7	21.9 ± 4.9	21.4 ± 4.9	22.1 ± 5.9	21.8 ± 4.9	22.0 ± 3.5
	C	16.6 ± 4.6	22.1 ± 4.2	22.1 ± 3.9	22.7 ± 4.0	23.2 ± 3.8	24.1 ± 5.0
Qs/Qt_*
	A	11.5 ± 1.7	16.8 ± 1.4	17.8 ± 1.2	18.4 ± 1.2	18.5 ± 1.5	17.0 ± 1.9
	B	7.8 ± 2.4^a	14.4 ± 2.6^a	14.7 ± 2.0^a	16.0 ± 2.0^a	15.7 ± 2.1^a	15.8 ± 1.4^a
	C	7.8 ± 2.6^a	14.0 ± 2.9^a	14.5 ± 2.4^a	15.2 ± 1.6^a	16.2 ± 1.6^a	15.3 ± 2.2^a

^aP < 0.05 compared with Group A; ^bP < 0.05 compared with Group B; *there is a difference at T1. (baseline), and the subsequent time points are adjusted with the level at T1
T1, pre-nebulization, T2, one-lung ventilation (OLV) 10 min, T3: OLV 15 min, T4: OLV 30 min, T5: OLV 60 min, T6: OLV 120 min
PaO₂, partial pressure of arterial oxygen; FiO₂, fraction of inspiration O₂; SaO₂, arterial oxygen saturation; SpO₂, percutaneous oxygen saturation; PaCO₂, arterial partial pressure of carbon dioxide; ETCO₂, end-tidal carbon dioxide; MAP, mean arterial pressure; PAW, airway pressure; A, 60% FiO₂ + 0.1 µg/kg PGE₁; B, 40% FiO₂ + 0.1 µg/kg PGE₁; C, 40% FiO₂ + 0.2 µg/kg PGE₁

Back to article page

ISSN: 1471-2466

Contact us

Submission enquiries: bmcpulmonarymedicine@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Pulmonary Medicine

Contact us